Skip to content

A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome.

A Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04111341
Enrollment
30
Registered
2019-10-01
Start date
2016-05-06
Completion date
2017-12-31
Last updated
2019-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjögren's Syndrome

Keywords

Sjögren's syndrome, Traditional Chinese Medicine, Herbs, Clinical trial, Gan-Lu-Yin, Jia-wei-Xiao-yao-San, Ye-Jiao-Teng, Suan-Zao-Ren

Brief summary

To investigate the efficacy and safety of traditional Chinese medicine in patients with Sjogren's syndrome.

Detailed description

This is 2 years' double blind, randomized, placebo-controlled clinical trial. Patients fulfilled the classification criteria of Sjogren syndrome will be recruited. Eligible subjects will be randomized on a 2:1 ratio to Traditional Chinese Medicine (TCM) granules or placebo for 12 weeks. The treatment group will receive a combination formula with traditional Chinese medicine, Gan-Lu-Yin in the morning and Jia-wei-Xiao-yao-San in the evening. Primary endpoint is the ESSPRI, European Sjogren Syndrome Patient Reported Outcome Index. Secondary endpoints include disease activity index (ESSDAI) , patient global assessment (PGA), VAS pain scale, Quality of Life by Short Form-36 (SF-36), fatigue scale and related serological markers. Thirty patients will be enrolled in the first year. After interim analysis at the end of first year, sample size will be recalculated base on the interim analysis results.

Interventions

DRUGTCM (Gan-Lu-Yin)GLY

TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks

DRUGPLACEBO

TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks

Sponsors

Chung Shan Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥20 years old * Written informed consent obtained * Been diagnosed with the diagnostic criteria for Sjogren's syndrome (according to the 2002 European Classification Standard) * The ESSPRI score of the patient of Sjogren's syndrome at least\> 3

Exclusion criteria

* Have association disease about heart, lung, nerve or mental * Pregnant or breastfeeding women * Laboratory abnormality: 1. Serum creatinine ≥2.0 mg/dl 2. Male: Hb≤9 g/dl;Female: Hb≤8.5 g/dl 3. Neutrophil or lymphocyte\<0.5 x 109/l

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at week 12week 0, week 12The investigators use ESSPRI to compared the difference between the week 12 and 0

Secondary

MeasureTime frameDescription
Physicians Global Assessment to measure quality of life (PGA)week 0, week 4, week 8, week 12The investigators use PGA to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0
Visual Analog Scale for pain (VAS)week 0, week 4, week 8, week 12The investigators use VAS to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0
Quality of life by SF-36week 0, week 4, week 8, week 12The investigators use SF-36 to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0
Change from baseline EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) at week 4week 0, week 4The investigators use ESSDAI to compared the difference between the the week 4 and 0
Pittsburgh Sleep Quality Index (PSQI)week 0, week 4, week 8, week 12The investigators use PSQI to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0
Body Constitution Questionnaire (BCQ)week 0, week 4, week 8, week 12The investigators use BCQ to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0
Change from baseline EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) at week 8week 0, week 8The investigators use ESSDAI to compared the difference between the week 8 and 0
modified fatigue impact scale (MFI)week 0, week 4, week 8, week 12The investigators use MFI to compared the difference between the week 12 and 0, the week 8 and 0, the week 4 and 0

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026